Cocrystal Pharma to Present Data from Phase 1 Study of First-in-Class Norovirus Protease Inhibitor CDI-988 at the 9th International Calicivirus Conference
Cocrystal Pharma (Nasdaq: COCP) announced that its first-in-class pan-viral protease inhibitor CDI-988 has been selected for oral presentation at the 9th International Calicivirus Conference in September 2025. The presentation will showcase Phase 1 study results of CDI-988, designed as a treatment for norovirus infections.
CDI-988 was developed using Cocrystal's proprietary structure-based platform technology as a broad-spectrum inhibitor targeting 3CL viral proteases. The company has completed a Phase 1 randomized, double-blind, placebo-controlled study evaluating safety, tolerability, and pharmacokinetics in healthy adults. The drug aims to address norovirus infections, which cause severe gastrointestinal illness with an estimated global societal cost of $60 billion annually.
Cocrystal Pharma (Nasdaq: COCP) ha annunciato che il suo inibitore pan-virale di proteasi di prima classe, CDI-988, è stato selezionato per una presentazione orale alla 9ª Conferenza Internazionale sul Calicivirus, che si terrà a settembre 2025. La presentazione illustrerà i risultati dello studio di Fase 1 su CDI-988, sviluppato come trattamento per le infezioni da norovirus.
CDI-988 è stato sviluppato utilizzando la tecnologia proprietaria di Cocrystal basata sulla struttura, come inibitore ad ampio spettro mirato alle proteasi virali 3CL. L'azienda ha completato uno studio di Fase 1 randomizzato, in doppio cieco e controllato con placebo per valutare sicurezza, tollerabilità e farmacocinetica in adulti sani. Il farmaco punta a contrastare le infezioni da norovirus, che causano gravi malattie gastrointestinali con un costo sociale globale stimato di 60 miliardi di dollari all'anno.
Cocrystal Pharma (Nasdaq: COCP) anunció que su inhibidor de proteasa pan-viral de primera clase, CDI-988, ha sido seleccionado para una presentación oral en la 9ª Conferencia Internacional sobre Calicivirus en septiembre de 2025. La presentación mostrará los resultados del estudio de Fase 1 de CDI-988, diseñado como tratamiento para infecciones por norovirus.
CDI-988 fue desarrollado utilizando la tecnología propietaria basada en estructura de Cocrystal como un inhibidor de amplio espectro dirigido a las proteasas virales 3CL. La compañía completó un estudio de Fase 1 aleatorizado, doble ciego y controlado con placebo para evaluar la seguridad, tolerabilidad y farmacocinética en adultos sanos. El medicamento busca tratar las infecciones por norovirus, que causan enfermedades gastrointestinales graves con un costo social global estimado de 60 mil millones de dólares anuales.
Cocrystal Pharma (나스닥: COCP)는 자사의 최초 클래스 범용 바이러스 프로테아제 억제제인 CDI-988이 2025년 9월에 열리는 제9회 국제 칼리시바이러스 학회에서 구두 발표로 선정되었다고 발표했습니다. 이번 발표에서는 노로바이러스 감염 치료제로 설계된 CDI-988의 1상 연구 결과를 공개할 예정입니다.
CDI-988은 Cocrystal의 독자적인 구조 기반 플랫폼 기술을 활용하여 3CL 바이러스 프로테아제를 표적으로 하는 광범위 억제제로 개발되었습니다. 회사는 건강한 성인을 대상으로 안전성, 내약성 및 약동학을 평가한 1상 무작위, 이중맹검, 위약 대조 연구를 완료했습니다. 이 약물은 심각한 위장관 질환을 일으키며 연간 전 세계 사회적 비용이 약 600억 달러에 달하는 노로바이러스 감염을 치료하는 것을 목표로 합니다.
Cocrystal Pharma (Nasdaq : COCP) a annoncé que son inhibiteur de protéase pan-viral de première classe, CDI-988, a été sélectionné pour une présentation orale lors de la 9e Conférence Internationale sur les Calicivirus en septembre 2025. Cette présentation mettra en avant les résultats de l'étude de Phase 1 de CDI-988, conçu comme traitement des infections à norovirus.
CDI-988 a été développé grâce à la technologie propriétaire de plateforme basée sur la structure de Cocrystal, en tant qu'inhibiteur à large spectre ciblant les protéases virales 3CL. La société a achevé une étude de Phase 1 randomisée, en double aveugle et contrôlée par placebo évaluant la sécurité, la tolérance et la pharmacocinétique chez des adultes sains. Ce médicament vise à traiter les infections à norovirus, responsables de maladies gastro-intestinales sévères, avec un coût sociétal mondial estimé à 60 milliards de dollars par an.
Cocrystal Pharma (Nasdaq: COCP) gab bekannt, dass sein neuartiger pan-viraler Proteaseinhibitor CDI-988 für eine mündliche Präsentation auf der 9. Internationalen Calicivirus-Konferenz im September 2025 ausgewählt wurde. Die Präsentation wird die Ergebnisse der Phase-1-Studie von CDI-988 vorstellen, das als Behandlung für Norovirus-Infektionen entwickelt wurde.
CDI-988 wurde mithilfe der firmeneigenen struktur-basierten Plattformtechnologie von Cocrystal als Breitbandinhibitor entwickelt, der auf 3CL-Virusproteasen abzielt. Das Unternehmen hat eine randomisierte, doppelblinde, placebokontrollierte Phase-1-Studie zur Bewertung von Sicherheit, Verträglichkeit und Pharmakokinetik bei gesunden Erwachsenen abgeschlossen. Das Medikament soll Norovirus-Infektionen behandeln, die schwere gastrointestinale Erkrankungen verursachen und weltweit geschätzte gesellschaftliche Kosten von 60 Milliarden US-Dollar jährlich verursachen.
- Novel pan-viral activity against all noroviruses including GII.4 and GII.17 strains
- Addresses an unmet medical need with no current approved vaccines or antivirals for norovirus
- Completion of Phase 1 clinical trial evaluating safety and pharmacokinetics
- Potential application for both noroviruses and coronaviruses
- None.
Insights
Cocrystal's upcoming Phase 1 data presentation for its first-in-class norovirus inhibitor represents modest clinical pipeline progress in an untapped market.
Cocrystal Pharma's upcoming presentation of Phase 1 data for CDI-988 at the International Calicivirus Conference represents incremental progress in developing the first antiviral treatment for norovirus. While the press release doesn't disclose the actual Phase 1 results, the company's willingness to present at a major scientific conference suggests the data likely met basic safety and pharmacokinetic objectives.
The market opportunity is substantial, with norovirus causing significant global disease burden and
CDI-988's mechanism as a pan-viral protease inhibitor targeting the conserved 3CL region is scientifically sound, potentially offering activity against multiple norovirus strains including GII.4 and GII.17. The molecule's potential dual activity against both noroviruses and coronaviruses could enhance its commercial value.
However, investors should recognize that Phase 1 studies only establish preliminary safety and pharmacokinetics in healthy volunteers - not efficacy. The compound remains early-stage, likely requiring years of additional development through Phase 2 and 3 trials before potential commercialization. The company's proprietary structure-based platform technology represents a potential competitive advantage for developing targeted antivirals with specific mechanisms of action.
BOTHELL, Wash., July 10, 2025 (GLOBE NEWSWIRE) -- Cocrystal Pharma, Inc. (Nasdaq: COCP) announces that its first-in-class pan-viral protease inhibitor CDI-988 has been selected for an oral presentation at the 9th International Calicivirus Conference being held September 7-11, 2025 in Banff, Alberta, Canada. Sam Lee, PhD, the Company’s President and co-CEO, will present “Oral Direct-Acting Antiviral CDI-988 for Norovirus Infection Prevention and Treatment: Mechanism of Action and Phase 1 Study Results” on September 11.
“This year’s Calicivirus Conference will bring together the world's leading norovirus experts, making it the ideal venue to share our pan-viral protease inhibitor CDI-988 Phase 1 data and clinical development strategy," said Dr. Lee. "Norovirus causes a highly contagious gastrointestinal illness, triggering severe vomiting and diarrhea, and has a substantial economic impact with a societal cost of approximately
Pan-Viral Inhibitor CDI-988
CDI-988 was designed and developed with Cocrystal’s proprietary structure-based platform technology as a broad-spectrum inhibitor to a highly conserved region in the active site of 3CL viral proteases. Based on a novel mechanism of action and superior broad-spectrum antiviral activity, CDI-988 represents a compelling first-in-class oral treatment for noroviruses, which are members of the calicivirus family, and for coronaviruses. Cocrystal has completed a single-center, randomized, double-blind, placebo-controlled Phase 1 study in healthy adults evaluating the safety, tolerability and pharmacokinetics of CDI-988, including a food effect cohort.
Structure-Based Platform Technology
Cocrystal’s proprietary structural biology, along with its expertise in enzymology and medicinal chemistry, enable its development of novel antiviral agents. The Company’s platform provides a three-dimensional structure of inhibitor complexes at near-atomic resolution, providing immediate insight to guide structure activity relationships. This helps to identify novel binding sites and allows for a rapid turnaround of structural information through highly automated X-ray data processing and refinement. The goal of this technology is to facilitate the development of best-in-class antiviral therapies that have fast onset of action or shortened treatment time, are safe, well tolerated and easy to administer, and are effective against all viral subtypes that cause disease and have a high barrier to viral resistance.
About the Calicivirus Conference
The International Calicivirus Conference is held every three years and unites scientists from across the globe who study calicivirus virology, evolution, pathogenesis, structural biology, diagnosis, epidemiology, treatment and prevention. The conference aims to foster open discussions, spark new collaborations and explore groundbreaking research. Delegates have the opportunity to engage with the latest advances in the field through state-of-the-art lectures, oral presentations and poster sessions.
About Cocrystal Pharma, Inc.
Cocrystal Pharma, Inc. is a clinical-stage biotechnology company discovering and developing novel antiviral therapeutics that target the replication process of influenza viruses, coronaviruses (including SARS-CoV-2), noroviruses and hepatitis C viruses. Cocrystal employs unique structure-based technologies and Nobel Prize-winning expertise to create first- and best-in-class antiviral drugs.
Cautionary Note Regarding Forward-Looking Statements
This press release contains forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995, including statements regarding the potential for the Company’s CDI-988 product candidate as a treatment for norovirus. The words "believe," "may," "estimate," "continue," "anticipate," "intend," "should," "plan," "could," "target," "potential," "is likely," "will," "expect" and similar expressions, as they relate to us, are intended to identify forward-looking statements. We have based these forward-looking statements largely on our current expectations and projections about future events. Some or all of the events anticipated by these forward-looking statements may not occur. Important factors that could cause actual results to differ from those in the forward-looking statements include, but are not limited to, our need for additional capital to fund our operations over the next 12 months, risks relating to our ability to obtain regulatory approval for and proceed with clinical trials including recruiting volunteers and procuring materials for such studies by our clinical research organizations and vendors, the results of such studies, our and our collaboration partners’ technology and software performing as expected, general risks arising from clinical studies, regulatory changes, and potential development of effective treatments and/or vaccines by competitors, potential mutations in a virus we are targeting that may result in variants that are resistant to a product candidate we develop, the impact of the Trump Administration’s policies and actions on regulation affecting the FDA and other healthcare agencies and potential staffing issues resulting therefrom, as well as other government actions such as tariffs which may cause delays or force us to incur additional costs to proceed without development programs. Further information on our risk factors is contained in our filings with the SEC, including our Annual Report on Form 10-K for the year ended December 31, 2024. Any forward-looking statement made by us herein speaks only as of the date on which it is made. Factors or events that could cause our actual results to differ may emerge from time to time, and it is not possible for us to predict all of them. We undertake no obligation to publicly update any forward-looking statement, whether as a result of new information, future developments or otherwise, except as may be required by law.
Investor Contact:
Alliance Advisors IR
Jody Cain
310-691-7100
jcain@allianceadvisors.com
# # #
FAQ
What are the key findings from COCP's Phase 1 study of CDI-988?
How does Cocrystal Pharma's CDI-988 work against norovirus?
What is the market potential for COCP's norovirus treatment CDI-988?
When will Cocrystal Pharma present the CDI-988 Phase 1 data?
What makes COCP's structure-based platform technology unique?
